4D MOLECULAR THERAPEUTICS IN (FDMT) Stock Analyst Ratings
USA - NASDAQ:FDMT - US35104E1001 - Common Stock
10.835 USD
-0.4 (-3.6%)
ChartMill assigns a Buy % Consensus number of 81% to FDMT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 31.04. This target is 186.45% above the current price.
FDMT was analyzed by 16 analysts. The buy percentage consensus is at 81. So analysts seem to be very confident about FDMT.
In the previous month the buy percentage consensus was at a similar level.
FDMT was analyzed by 16 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-21 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-08-12 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-12 | Roth Capital | Maintains | Buy -> Buy |
| 2025-08-01 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-07-03 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-09 | Barclays | Maintains | Overweight -> Overweight |
| 2025-05-09 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-03-10 | B of A Securities | Maintains | Buy -> Buy |
| 2025-03-04 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-03 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-03-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-11 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-02-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-13 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-01-13 | Morgan Stanley | Maintains | Underweight -> Underweight |
| 2025-01-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-18 | B of A Securities | Maintains | Buy -> Buy |
| 2024-11-21 | Morgan Stanley | Initiate | Underweight |
| 2024-11-14 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-11-14 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-11-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-23 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2024-09-19 | Leerink Partners | Reiterate | Outperform -> Outperform |
| 2024-09-19 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-09-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-09 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-08-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-22 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-07-18 | BMO Capital | Maintains | Outperform -> Outperform |